Skip to main content

Table 1 Repeated measure ANOVA results and post-hoc means of the physicochemical conditions to all treatments throughout time

From: Multi-domain probiotic consortium as an alternative to chemical remediation of oil spills at coral reefs and adjacent sites

Parameters

 

F value

p value

Post-Hoc (Mean ± SE)

pH

Time

2.03

0.14

 
 

Treatments

32.02

< 0.0001

 
 

Time:Treatments

0.58

0.86

 
 

Post-hoc comparison

  

Corexit 9500 ( 8.05 ± 0.04)

    

oWSF + Corexit 9500 (7.99 ± 0.04)

    

oWSF + pBMC-BC + Corexit 9500 (8.06 ± 0.04)

    

oWSF (8.34 ± 0.04)

    

pBMC-BC (8.54 ± 0.04)

    

oWSF + pBMC-BC (8.61 ± 0.04)

    

Control (8.47 ± 0.04)

DOC

Time

11.24

< 0.001

 
 

Treatments

1.51

0.21

 
 

Time:Treatments

1.22

0.29

 
 

Post-hoc comparison

  

T0 (3.24 μg/mL ± 0.26)

    

T1 (4.44 mg/mL ± 0.26)

    

T2 (4.53 μg/mL ± 0.26)

Salinity

Time

78.9

< 0.0001

 
 

Treatments

2.8

0.03

 
 

Time:Treatments

1.6

0.11

 
 

Post-hoc comparison

  

T0 (36.22 mg/L ± 0.07)

    

T1 (36.17 mg/L ± 0.07)

    

T2 (37.25 mg/L ± 0.07)

    

Control (36.70 mg/L ± 0.12)

    

oWSF (36.42 mg/L ± 0.12)

    

pBMC-BC (36.74 mg/L ± 0.12)

    

Corexit 9500 (36.60 mg/L ± 0.12)

    

oWSF + pBMC-BC (36.20 mg/L ± 0.14)

    

oWSF + Corexit 9500 (36.38 mg/L ± 0.12)

    

pBMC-BC + Corexit 9500 (36.85 mg/L ± 0.12)

    

oWSF + pBMC-BC + Corexit 9500 (36.47 mg/L ± 0.12)

Ammonium

Time

14.86

< 0.0001

 
 

Treatments

1.33

0.28

 
 

Time:Treatments

1.07

0.41

 
 

Post-hoc comparison

  

T0 (28.10 μg/L ± 19.22)

    

T1 (160.09 μg/L ± 19.22)

    

T2 (99.83 μg/L ± 19.22)

Nitrate

Time

6.88

0.002

 
 

Treatments

0.35

0.92

 
 

Time:Treatments

0.72

0.74

 
 

Post-hoc comparison

  

T0 (6.56 μg/L ± 10.76)

    

T1 (58.11 μg/L ± 10.76)

    

T2 (34.65 μg/L ± 10.76)

Phosphate

Time

20.21

< 0.0001

 
 

Treatments

5.59

< 0.001

 
 

Time:Treatments

3.37

< 0.001

 
 

Post-hoc comparison

  

Control in T0 (18.65 μg/L ± 23.19), T1 (61.80 μg/L ± 23.19) and T2 (33.82 μg/L ± 23.19)

    

oWSF in T0 (13.96 μg/L ± 23.19), T1 (25.24 μg/L ± 23.19) and T2 (17.26 μg/L ± 23.19)

    

pBMC-BC in T0 (5.97 μg/L ± 23.19), T1 (51.55 μg/L ± 23.19) and T2 (70.67 μg/L ± 23.19)

    

Corexit 9500 in T0 (3.22 μg/L ± 23.19), T1 (234.27 μg/L ± 23.19) and T2 (136.47 μg/L ± 23.19)

    

oWSF + pBMC-BC in T0 (6.76 μg/L ± 23.19), T1 (56.20 μg/L ± 23.19) and T2 (97.50 μg/L ± 23.19)

    

oWSF + Corexit 9500 in T0 (0 μg/L ± 23.19), T1 (83.35 μg/L ± 23.19) and T2 (53.00 μg/L ± 23.19)

    

pBMC-BC + Corexit 9500 in T0 (3.22 μg/L ± 23.19), T1 (3.77 μg/L ± 23.19) and T2 (109.82 μg/L ± 23.19)

    

oWSF + pBMC-BC + Corexit 9500 in T0 (3.77 μg/L ± 23.19), T1 (78.75 μg/L ± 23.19) and T2 (34.20 μg/L ± 23.19)

PAH

Time

7.86

0.001

 
 

Treatments

20.86

< 0.0001

 
 

Time:Treatments

3.31

0.001

 
 

Post-hoc comparison

  

Control in T0 (1.63 μg/L ± 467.05), T1 (0.48 μg/L ± 467.05) and T2 (0.58 μg/L ± 467.05)

    

oWSF in T0 (4.36 μg/L ± 467.05), T1 (0.61 μg/L ± 467.05) and T2 (1.26 μg/L ± 467.05)

    

pBMC-BC in T0 (0.08 μg/L ± 467.05), T1 (0.06 μg/L ± 467.05) and T2 (0.10 μg/L ± 467.05)

    

Corexit 9500 in T0 (17.72 μg/L ± 467.05), T1 (5.99 μg/L ± 467.05) and T2 (4.99 μg/L ± 467.05)

    

oWSF + pBMC-BC in T0 (3.39 μg/L ± 539.30), T1 (0.03 μg/L ± 539.30) and T2 (0.14 μg/L ± 539.30)

    

oWSF + Corexit 9500 in T0 (803.19 μg/L ± 467.05), T1 (4665.46 μg/L ± 467.05) and T2 (2711.75 μg/L ± 467.05)

    

pBMC-BC + Corexit 9500 in T0 (8.60 μg/L ± 467.05), T1 (9.39 μg/L ± 467.05) and T2 (3.94 μg/L ± 467.05)

    

oWSF + pBMC-BC + Corexit 9500 in T0 (1162.94 μg/L ± 467.05), T1 (4559.76 μg/L ± 467.05) and T2 (2165.55 μg/L ± 467.05)

N-alkanes

Time

4.84

0.013

 
 

Treatments

9.98

< 0.0001

 
 

Time:Treatments

2.21

0.022

 
 

Post-hoc comparison

  

Control in T0 (1.63 μg/L ± 467.05), T1 (0.48 μg/L ± 467.05) and T2 (0.58 μg/L ± 467.05)

    

oWSF in T0 (4.36 μg/L ± 467.05), T1 (0.61 μg/L ± 467.05) and T2 (1.26 μg/L ± 467.05)

    

pBMC-BC in T0 (0.08 μg/L ± 467.05), T1 (0.06 μg/L ± 467.05) and T2 (0.10 μg/L ± 467.05)

    

Corexit 9500 in T0 (17.72 μg/L ± 467.05), T1 (5.99 μg/L ± 467.05) and T2 (4.99 μg/L ± 467.05)

    

oWSF + pBMC-BC in T0 (3.39 μg/L ± 539.30), T1 (0.03 μg/L ± 539.30) and T2 (0.14 μg/L ± 539.30)

    

oWSF + Corexit 9500 in T0 (803.19 μg/L ± 467.05), T1 (4665.46 μg/L ± 467.05) and T2 (2711.75 μg/L ± 467.05)

    

pBMC-BC + Corexit 9500 in T0 (8.60 μg/L ± 467.05), T1 (9.39 μg/L ± 467.05) and T2 (3.94 μg/L ± 467.05)

    

oWSF + pBMC-BC + Corexit 9500 in T0 (1162.94 μg/L ± 467.05), T1 (4559.76 μg/L ± 467.05) and T2 (2165.55 μg/L ± 467.05)